Cypress Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$476K Hold
6,000
0.13% 74
2026
Q1
$451K Sell
6,000
-4,000
-40% -$316K 0.13% 69
2025
Q4
$791K Hold
10,000
0.22% 56
2025
Q3
$654K Hold
10,000
0.19% 60
2025
Q2
$395K Hold
10,000
0.11% 68
2025
Q1
$302K Hold
10,000
0.09% 69
2024
Q4
$350K Hold
10,000
0.1% 65
2024
Q3
$401K Hold
10,000
0.1% 67
2024
Q2
$477K Hold
10,000
0.12% 67
2024
Q1
$434K Buy
+10,000
New +$477K 0.12% 63
2021
Q2
Sell
-25
Closed -$1K 95
2021
Q1
$1K Buy
+25
New +$1.39K ﹤0.01% 101

Other funds holding IONS

Cypress Capital's IONS Position: Q2 2026 in Review

Cypress Capital held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 6,000 shares worth $476K. The position accounts for 0.13% of the portfolio, ranked #74.

Cypress Capital first reported a position in IONS in Q1 2021 and has held it in 11 quarters since. The position peaked at $791K in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Cypress Capital held 6,000 shares of Ionis Pharmaceuticals worth $476K as of Q2 2026.
  • Cypress Capital left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up 0.13% of Cypress Capital's portfolio in Q2 2026, its #74 holding.
  • Cypress Capital first reported a position in Ionis Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • Cypress Capital's Ionis Pharmaceuticals position peaked at $791K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Cypress Capital's 13F filing for Q2 2026, filed 17 Jul 2026.